Considering the use of cardioprotective drugs, such as SGLT-2 inhibitors or GLP-1 receptor agonists, in patients with and without diabetes, it is valuable to evaluate their impact on the TyG index and potential benefits in reducing in-hospital mortality and MACCE after STEMI and NSTEMI [30, 31]. This evidence concerns the gene SLC5A2 and diabetes mellitus.